Using minibeam radiation to improve delivery of cancer-fighting nanoparticles to pancreatic tumors
Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors
This study is exploring a new way to help deliver tiny cancer-fighting particles directly to pancreatic tumors using a special type of radiation therapy, which could make treatments more effective and safer for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11054612 on NIH RePORTER |
What this research studies
This research investigates a novel approach to enhance the delivery of nanoparticle anticancer agents specifically to pancreatic cancer tumors. By utilizing minibeam radiation therapy (MRT), which has unique characteristics compared to traditional radiation methods, the study aims to improve the uptake of these nanoparticles in solid tumors. The researchers believe that MRT can modify tumor blood vessels and increase blood flow, thereby allowing more nanoparticles to reach the tumor site effectively. This innovative method could potentially lead to more effective and safer cancer treatments for patients with pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who may benefit from advanced treatment options.
Not a fit: Patients with cancers other than pancreatic cancer or those who are not eligible for nanoparticle therapies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with pancreatic cancer by enhancing the effectiveness of nanoparticle-based therapies.
How similar studies have performed: Previous studies have shown promise in using innovative radiation therapies to enhance drug delivery, suggesting that this approach may yield successful outcomes.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Zamboni, William C — Univ of North Carolina Chapel Hill
- Study coordinator: Zamboni, William C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.